Breakthrough in Cancer Research
In a groundbreaking study published in the Journal of Clinical Investigation on March 3, 2026, scientists from Duke-NUS Medical School have unveiled a pivotal molecular mechanism governing pancreatic cancer's notorious resistance to chemotherapy.
The newly identified molecular "switch" centers on the dynamic plasticity of pancreatic cancer cells, which allows them to shift between more treatable and highly resistant identities. At the core of this plasticity lies the gene GATA6, a master regulator responsible for maintaining the differentiated, less aggressive phenotype of pancreatic tumors.
"While it has been recognized that pancreatic cancer cells can shift between differentiated and resistant states, the molecular underpinnings of this process remained elusive. Our work identifies the signaling axis responsible for suppressing GATA6 and thereby promotes a resistant phenotype."
The Challenge of Pancreatic Cancer
Pancreatic cancer has long posed a formidable challenge to oncologists worldwide. Despite being the ninth most common cancer in Singapore, it ranks as the fourth leading cause of cancer mortality. Because symptoms often appear late and current treatments have limited impact, most patients depend on chemotherapy, which typically provides only modest benefit.
Over the past decade, scientists have identified two main molecular subtypes of pancreatic cancer: classical and basal. Tumors in the classical subtype tend to be more organized at the cellular level, making them more susceptible to treatment. In contrast, basal subtype tumors are more disorganized and aggressive, and they are often resistant to chemotherapy.
The Role of GATA6 in Tumor Behavior
Importantly, pancreatic cancer cells are not fixed in one subtype. They can shift between these states, moving from a more treatable form to a more resistant one. This flexibility is known as cancer cell plasticity.
The research team focused on a gene called GATA6, which when expressed at high levels, enforces a structured cellular architecture that renders cancer cells more susceptible to chemotherapeutic agents. Conversely, diminished GATA6 expression correlates with a loss of cellular organization, ushering in an aggressive, treatment-resistant basal state.
A Path Forward
The study's lead author, Professor David Virshup from Duke-NUS Medical School, explained how this discovery works at the molecular level: oncogenic KRAS mutations drive a pathway that suppresses GATA6. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemotherapy.
"Our work identifies the signaling axis responsible for suppressing GATA6 and thereby promotes a resistant phenotype. The results suggest that pairing targeted therapies with standard chemotherapy may improve outcomes for patients whose tumors no longer respond to treatment."
This discovery could help turn some of the toughest pancreatic tumors into ones doctors can better control through existing drugs, offering new hope for patients facing one of the deadliest cancers worldwide.
The research team includes Zhong et al., with photomicrographs enhanced using AI tools to better visualize the molecular changes in pancreatic cancer xenografts. The findings have been published in the Journal of Clinical Investigation, opening new avenues for therapeutic combinations that could transform patient outcomes in oncology.